However, recent findings demonstrated that combining a HIF-2α inhibitor with anti-CTLA-4 significantly slowed tumor growth in a pancreatic adenocarcinoma mouse model compared to anti-CTLA-4 alone, with further addition of anti-PD-1 extending median survival compared to vehicle or HIF-2α inhibitor alone, though not significantly beyond dual ICB therapy [13]. The gene discussed is CTLA4; the disease is neoplasm.